Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
18.42B
Market cap18.42B
Price-Earnings ratio
14.44
Price-Earnings ratio14.44
Dividend yield
Dividend yield
Average volume
1.60M
Average volume1.60M
High today
$93.64
High today$93.64
Low today
$91.28
Low today$91.28
Open price
$93.25
Open price$93.25
Volume
1.65M
Volume1.65M
52 Week high
$112.29
52 Week high$112.29
52 Week low
$53.56
52 Week low$53.56

Stock Snapshot

Incyte(INCY) stock is priced at $92.54, giving the company a market capitalization of 18.42B. It carries a P/E multiple of 14.44.

As of 2026-03-14, Incyte(INCY) stock has fluctuated between $91.28 and $93.64. The current price stands at $92.54, placing the stock +1.4% above today's low and -1.2% off the high.

Incyte(INCY) shares are trading with a volume of 1.65M, against a daily average of 1.6M.

During the past year, Incyte(INCY) stock moved between $53.56 at its lowest and $112.29 at its peak.

During the past year, Incyte(INCY) stock moved between $53.56 at its lowest and $112.29 at its peak.

INCY News

TipRanks 3d
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing

Incyte (INCY) announced an update on their ongoing clinical study. Incyte Corp. has launched a Phase 1 study called “A Study to Evaluate the Pharmacokinetics,...

TipRanks 3d
Incyte’s Ruxolitinib Pediatric Leukemia Study Update: What Investors Should Watch

Incyte (INCY) announced an update on their ongoing clinical study. Incyte Inc. (INCY) has updated a Phase 2 study called “A Phase 2 Study of the JAK1/JAK2 Inhi...

Simply Wall St 7d
Assessing Incyte Valuation After EC Approval Of Zynyz For Advanced Anal Cancer

Advertisement EC approval of Zynyz sets fresh context for Incyte’s stock story Incyte (INCY) just received European Commission approval for Zynyz, used with c...

Assessing Incyte Valuation After EC Approval Of Zynyz For Advanced Anal Cancer

Analyst ratings

46%

of 28 ratings
Buy
42.9%
Hold
46.4%
Sell
10.7%

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.